Why the study?
Does upgrading to cardiac resynchronization therapy improve left ventricular systolic dysfunction in a patient with systemic sclerosis and pacemaker-induced cardiomyopathy?
Does upgrading to cardiac resynchronization therapy improve left ventricular systolic dysfunction in a patient with systemic sclerosis and pacemaker-induced cardiomyopathy?
In patients with systemic sclerosis, subclinical LV systolic dysfunction may be present and worsened by RV pacing, which can be detected by speckle-tracking echocardiography and improved by upgrading to CRT.
Answers are grounded in this paper and cite their sources.
May support CRT upgrade consideration in systemic sclerosis with pacing cardiomyopathy; leaves open generalizability and GLS role pending prospective data.
A 58-year-old man suffering from systemic sclerosis was admitted to our hospital because of heart failure. He developed atrioventricular block 4 months previously and had a pacemaker implanted, after which left ventricular wall motion markedly worsened. The global longitudinal strain was already decreased before the onset of atrioventricular block, although the left ventricular ejection fraction was normal. Right ventricular pacing was suspected to have caused overt left ventricular systolic dysfunction. Therefore, right ventricular pacing was upgraded to cardiac resynchronization therapy. After this change, the left ventricular ejection fraction improved to almost normal, but global longitudinal strain remained decreased. The findings in our case suggest that some patients with systemic sclerosis already have subclinical left ventricular systolic dysfunction before the onset of atrioventricular block. Additionally, right ventricular pacing may cause further deterioration of left ventricular systolic function and heart failure. Learning objective: The possibility of subclinical left ventricular systolic dysfunction associated with systemic sclerosis should be considered when implanting a pacemaker. Speckle-tracking echocardiography may also be useful in the management of patients with systemic sclerosis.
No takes yet. Share an insight, caveat, or question.
Yamasaki et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: